| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 24/02/2025 | 13:43 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PEPG | PepGen Inc |
| 24/02/2025 | 13:30 | Business Wire | PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights | NASDAQ:PEPG | PepGen Inc |
| 24/02/2025 | 13:00 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:PEPG | PepGen Inc |
| 24/02/2025 | 13:00 | Business Wire | PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 | NASDAQ:PEPG | PepGen Inc |
| 29/01/2025 | 22:05 | Business Wire | PepGen Announces CONNECT Program Updates | NASDAQ:PEPG | PepGen Inc |
| 16/12/2024 | 14:00 | Business Wire | PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy | NASDAQ:PEPG | PepGen Inc |
| 21/11/2024 | 22:05 | Business Wire | PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development | NASDAQ:PEPG | PepGen Inc |
| 07/11/2024 | 14:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:PEPG | PepGen Inc |
| 07/11/2024 | 14:00 | Business Wire | PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | NASDAQ:PEPG | PepGen Inc |
| 04/11/2024 | 14:00 | Business Wire | PepGen to Participate in Upcoming Investor Conferences | NASDAQ:PEPG | PepGen Inc |
| 08/10/2024 | 13:00 | Business Wire | PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society | NASDAQ:PEPG | PepGen Inc |
| 19/09/2024 | 22:30 | Business Wire | PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors | NASDAQ:PEPG | PepGen Inc |
| 20/08/2024 | 22:05 | Business Wire | PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development | NASDAQ:PEPG | PepGen Inc |
| 20/08/2024 | 14:00 | Business Wire | PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development | NASDAQ:PEPG | PepGen Inc |
| 08/08/2024 | 14:00 | Business Wire | PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | NASDAQ:PEPG | PepGen Inc |
| 30/07/2024 | 22:02 | Business Wire | PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy | NASDAQ:PEPG | PepGen Inc |
| 26/07/2024 | 22:52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PEPG | PepGen Inc |
| 09/07/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:PEPG | PepGen Inc |
| 02/07/2024 | 14:00 | Business Wire | PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications | NASDAQ:PEPG | PepGen Inc |
| 11/06/2024 | 13:00 | Business Wire | PepGen Announces Executive Team Promotions | NASDAQ:PEPG | PepGen Inc |
| 05/06/2024 | 22:22 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:PEPG | PepGen Inc |
| 14/05/2024 | 22:02 | GlobeNewswire Inc. | PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights | NASDAQ:PEPG | PepGen Inc |
| 13/03/2024 | 12:00 | GlobeNewswire Inc. | PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy | NASDAQ:PEPG | PepGen Inc |
| 06/03/2024 | 22:01 | GlobeNewswire Inc. | PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments | NASDAQ:PEPG | PepGen Inc |
| 04/03/2024 | 13:00 | GlobeNewswire Inc. | PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy | NASDAQ:PEPG | PepGen Inc |
| 20/02/2024 | 14:00 | GlobeNewswire Inc. | PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 | NASDAQ:PEPG | PepGen Inc |
| 07/02/2024 | 22:55 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:PEPG | PepGen Inc |
| 07/02/2024 | 13:30 | GlobeNewswire Inc. | PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock | NASDAQ:PEPG | PepGen Inc |
| 17/01/2024 | 13:00 | GlobeNewswire Inc. | Mary Beth DeLena Joins PepGen as General Counsel and Secretary | NASDAQ:PEPG | PepGen Inc |
| 08/01/2024 | 13:00 | GlobeNewswire Inc. | PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping | NASDAQ:PEPG | PepGen Inc |
